Oxford Nanopore Technologies
Founded Year
2005Stage
IPO | IPOTotal Raised
$1.179BDate of IPO
9/30/2021Market Cap
1.95BAbout Oxford Nanopore Technologies
Oxford Nanopore Technologies develops a nanopore DNA sequencer, the MinION. The MinION is a portable, real-time, long-read, low-cost device that has been designed to bring easy biological analyses to anyone, whether in scientific research, education or a range of real world applications such as disease/pathogen surveillance, environmental monitoring, food chain surveillance, self-quantification or even microgravity biology.
Missing: Oxford Nanopore Technologies's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Oxford Nanopore Technologies's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Research containing Oxford Nanopore Technologies
Get data-driven expert analysis from the CB Insights Intelligence Unit.
CB Insights Intelligence Analysts have mentioned Oxford Nanopore Technologies in 5 CB Insights research briefs, most recently on Jan 11, 2023.
May 18, 2020
Funding Trends In Europe’s Digital Health Space
Mar 12, 2020
100+ Of The Most Well-Funded Medical Device StartupsExpert Collections containing Oxford Nanopore Technologies
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Oxford Nanopore Technologies is included in 5 Expert Collections, including Medical Devices.
Medical Devices
8,847 items
Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.
Health Monitoring & Diagnostics
3,299 items
Companies developing or offering products that aid in the assessment, screening, diagnosis, or monitoring of a person's state of health/wellness. Excludes companies focused solely on fitness/sports performance
Omics
1,267 items
Companies involved in the capture, sequencing, and/or analysis of genomic, transcriptomic, proteomic, and/or metabolomic data
Digital Health
13,069 items
Technologies, platforms, and systems that engage consumers for lifestyle, wellness, or health-related purposes; capture, store, or transmit health data; and/or support life science and clinical operations. (DiME, DTA, HealthXL, & NODE.Health)
Health IT
7,901 items
Oxford Nanopore Technologies Patents
Oxford Nanopore Technologies has filed 204 patents.
The 3 most popular patent topics include:
- Molecular biology
- DNA
- Biotechnology
Application Date | Grant Date | Title | Related Topics | Status |
|---|---|---|---|---|
1/9/2019 | 1/24/2023 | Molecular biology, Proteomics, RNA, Biotechnology, Genetics | Grant |
Application Date | 1/9/2019 |
|---|---|
Grant Date | 1/24/2023 |
Title | |
Related Topics | Molecular biology, Proteomics, RNA, Biotechnology, Genetics |
Status | Grant |
Latest Oxford Nanopore Technologies News
Jan 30, 2023
About IP Group IP Group develops world-changing science and technology businesses across life sciences, technology and cleantech (through Kiko Ventures). The Group has a strong track record of success, having been the founder investor in a number of high-profile companies including Oxford Nanopore Technologies plc, and has one of the most exciting portfolios of high-growth businesses in Europe. The Group also owns Parkwalk, the UK's largest growth EIS fund manager which backs world-changing technologies emerging from the UK’s leading universities and research institutions. IP Group is listed on the Main Market of the London Stock Exchange under the code IPO. For more information, please visit our website at www.ipgroupplc.com . ENDS
Oxford Nanopore Technologies Frequently Asked Questions (FAQ)
When was Oxford Nanopore Technologies founded?
Oxford Nanopore Technologies was founded in 2005.
Where is Oxford Nanopore Technologies's headquarters?
Oxford Nanopore Technologies's headquarters is located at Gosling Building, Oxford.
What is Oxford Nanopore Technologies's latest funding round?
Oxford Nanopore Technologies's latest funding round is IPO.
How much did Oxford Nanopore Technologies raise?
Oxford Nanopore Technologies raised a total of $1.179B.
Who are the investors of Oxford Nanopore Technologies?
Investors of Oxford Nanopore Technologies include IP Group, Nikon, Wellington Management, Temasek, M&G Investments and 18 more.
Who are Oxford Nanopore Technologies's competitors?
Competitors of Oxford Nanopore Technologies include Chembio , Ellume, Visby Medical, Baebies, Cardea Bio, MeMed, Accellix, Inflammatix, LumiraDx, Cue Health and 27 more.
Compare Oxford Nanopore Technologies to Competitors
Visby Medical is transforming the order of diagnosis and treatment for infectious diseases so clinicians can test, talk with, and treat the patient in a single visit. The company’s technology development program culminated in an instrument-free, single-use PCR platform that rapidly tests for serious infections. Originally developed for sexually transmitted infections, the Company’s FDA-cleared, CLIA-waived Sexual Health Click Test for women returns accurate results within 28 minutes. Visby Medical technology also offers the Visby Medical COVID-19 Test, and its robust pipeline includes tests for other infectious diseases. It was founded in 2015 and is based in San Jose, California.
Torus Biosystems develops a syndromic diagnostic device designed for use in testing DNA for scientific and medical research purposes. Its Torus Synestia System provides seamless, comprehensive, sample-to-insight test results for major infectious diseases in a faster format than conventional methods, helping for better patient care and improved outcomes. The company was founded in 2019 and is based in Cambridge, Massachusetts.
Weavr Health is dedicated to connecting people to health by simplifying sample collection and processing for healthcare. The Velvet device is designed so anyone, anywhere can easily collect high-quality samples without a phlebotomist. The Velvet device offers a smooth experience of blood self-collection for patients. It leverages a similar experience to traditional glucose testing, which >25% of people have experienced. Each device arrives with all that is needed to collect, package and ship quality samples to the lab for a convenient experience.
Binx Health is an in vitro diagnostics Point-of-Care (POC) company that provides at-home STI testing. The platform also includes evidence-based testing, counseling, treatment, and follow up in order to increase screening and reduce infections.
Baebies developed a nimble bioassay automation platform to rapidly perform multiplex enzymatic assays and other tests. The company licensed its core technology, digital microfluidics, from Illumina. In addition to a technology license in newborn screening that does not include sequencing, Baebies also received equipment, contracts, and other consideration in exchange for a share of ownership in the new company. The company was founded in 2013 and is based in Durham, North Carolina.
Hemex creates affordable, life-changing medical diagnostics for under-served people everywhere. Its diagnostic platform is designed to reach populations at risk for malaria and sickle cell disease.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.